Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Feb 1;578(Pt 3):715-33.
doi: 10.1113/jphysiol.2006.121111. Epub 2006 Nov 23.

Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice

Andrew D Grant  1 , Graeme S Cottrell, Silvia Amadesi, Marcello Trevisani, Paola Nicoletti, Serena Materazzi, Christophe Altier, Nicolas Cenac, Gerald W Zamponi, Francisco Bautista-Cruz, Carlos Barajas Lopez, Elizabeth K Joseph, Jon D Levine, Wolfgang Liedtke, Stephen Vanner, Nathalie Vergnolle, Pierangelo Geppetti, Nigel W Bunnett
Affiliations

Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice

Andrew D Grant et al. J Physiol. .

Abstract

Exacerbated sensitivity to mechanical stimuli that are normally innocuous or mildly painful (mechanical allodynia and hyperalgesia) occurs during inflammation and underlies painful diseases. Proteases that are generated during inflammation and disease cleave protease-activated receptor 2 (PAR2) on afferent nerves to cause mechanical hyperalgesia in the skin and intestine by unknown mechanisms. We hypothesized that PAR2-mediated mechanical hyperalgesia requires sensitization of the ion channel transient receptor potential vanilloid 4 (TRPV4). Immunoreactive TRPV4 was coexpressed by rat dorsal root ganglia (DRG) neurons with PAR2, substance P (SP) and calcitonin gene-related peptide (CGRP), mediators of pain transmission. In PAR2-expressing cell lines that either naturally expressed TRPV4 (bronchial epithelial cells) or that were transfected to express TRPV4 (HEK cells), pretreatment with a PAR2 agonist enhanced Ca2+ and current responses to the TRPV4 agonists phorbol ester 4alpha-phorbol 12,13-didecanoate (4alphaPDD) and hypotonic solutions. PAR2-agonist similarly sensitized TRPV4 Ca2+ signals and currents in DRG neurons. Antagonists of phospholipase Cbeta and protein kinases A, C and D inhibited PAR2-induced sensitization of TRPV4 Ca2+ signals and currents. 4alphaPDD and hypotonic solutions stimulated SP and CGRP release from dorsal horn of rat spinal cord, and pretreatment with PAR2 agonist sensitized TRPV4-dependent peptide release. Intraplantar injection of PAR2 agonist caused mechanical hyperalgesia in mice and sensitized pain responses to the TRPV4 agonists 4alphaPDD and hypotonic solutions. Deletion of TRPV4 prevented PAR2 agonist-induced mechanical hyperalgesia and sensitization. This novel mechanism, by which PAR2 activates a second messenger to sensitize TRPV4-dependent release of nociceptive peptides and induce mechanical hyperalgesia, may underlie inflammatory hyperalgesia in diseases where proteases are activated and released.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression of TRPV4 in HBE cells and HEK cells A, RT-PCR of HBE cells showing amplification of transcripts for PAR2 and TRPV4 isoforms a, b and c There were no signals when reverse transcriptase (RT) was omitted (control). B, structure of three TRPV4 isoforms cloned from HBE cells. C, transient expression of TRPV4 isoforms with HA.11 tag in HEK cells. Immunoreactive TRPV4 was detected by immunofluorescence (left) and Western blotting (right) using HA.11 antibody. vc, vector control without TRPV4 insert. Scale bar = 10 μm.
Figure 2
Figure 2
Activation of TRPV4 in HBE cells and HEK cells Effects of 4αPDD (0.1–10 μm, upper traces) and hypotonic stimuli (260–310 mosmol l−1, lower traces) on [Ca2+]i in HBE cells (A) and HEK cells transiently expressing TRPV4 isoforms a, b or c or vector control (B). Left panels show records of [Ca2+]i expressed as 340/380 nm emission ratio as a percentage of response measured at 50 s (prestimulus, 100%). Right panels show [Ca2+]i responses as difference in 340/380 nm emission ratio between 50 s (prestimulus) and 300 s (maximal response). 4αPDD and hypotonic stimuli caused graded increases in [Ca2+]i in HBE cells and HEK-TRPV4a cells, but had no effect in HEK cells expressing b or c TRPV4 isoforms or vector control. *P < 0.05, ANOVA and Dunnett's test, n = 9 experiments.
Figure 4
Figure 4
Mechanisms of PAR2-induced sensitization of TRPV4 Ca2+ signals Effects of antagonists of signalling pathways on PAR2-induced sensitization of Ca2+ signals to 4αPDD (0.1 or 1 μm) (A) and hypotonic stimulus (260 mosmol l−1) (B) in HBE cells and to 4αPDD in HEK-TRPV4a cells (C). Cells were pretreated with PAR2-AP or PAR2-RP (both 100 μm) for 10 min before challenge with TRPV4 agonists. U73122 (10 μm), H-89 (10 μm), GF109203X (GFX) 10 μm and Gö6976 (0.1 μm), but not Gö6963 (0.1 μm), inhibited PAR2-induced sensitization of Ca2+ responses to 4αPDD in HBE cells and HEK-TRPV4a cells. U73122, H-89 and Gö6976, but not GF109203X or Gö6963, inhibited PAR2-induced sensitization of Ca2+ responses to hypotonic stimulus in HBE cells. Veh, vehicle; *P < 0.05; ANOVA followed by Dunnett's test; n = 8–12 experiments.
Figure 3
Figure 3
PAR-induced sensitization of TRPV4 Ca2+ signals A, B, C, left panels show records of [Ca2+]i after challenge with PAR2-AP, PAR2-RP (both 100 μm) or vehicle (veh) (A and B) or PAR1-AP, PAR1-RP (both 100 μm) or vehicle (C) at 50 s followed by 4αPDD (0.1 or 1 μm) or hypotonic stimulus (260 mosmol l−1) at 350 s. Traces are from HBE cells (A) and HEK-TRPV4a cells (B and C). [Ca2+]i is expressed as 340/380 nm emission ratio as a percentage of response measured at 50 s (prestimulus, 100%). Right panels show [Ca2+]i responses as difference in 340/380 nm emission ratio between 350 s (prestimulus) and 550 s (maximal response). Pretreatment with PAR2-AP but not PAR1-AP increased Ca2+ responses to 4αPDD and hypotonic stimulus, indicative of TRPV4 sensitization. *P < 0.05, ANOVA and Bonferroni's test, n = 9 experiments.
Figure 5
Figure 5
Localization and expression of TRPV4 in HEK cells and DRG neurons A, localization of TRPV4a transiently expressed in HEK cells by immunofluorescence using antibodies to HA.11 epitope or TRPV4. Both antibodies detected immunoreactive TRPV4. Control shows preabsorption of TRPV4 antibody with antigen used for immunization. B, localization of immunoreactive TRPV4, PAR2, CGRP or SP in sections of rat DRG. TRPV4 was detected in the soma at the plasma membrane (white arrowheads) and in intracellular locations (white arrows), and also in fibres (white arrows). White arrows show that some neurons coexpressed TRPV4 with PAR2, CGRP or SP. Yellow arrows show that some neurons expressing CGRP or SP did not express TRPV4. Yellow asterisks show that some neurons expressing TRPV4 did not express PAR2, CGRP or SP. Control shows preabsorption of TRPV4 antibody. Scale bar = 10 μm c, Localization of immunoreactive TRPV4, PAR2, CGRP or SP in rat DRG after 2 days in culture. White arrows denote colocalization of TRPV4 with PAR2, CGRP or SP. Yellow arrows show that some neurons expressing CGRP did not express TRPV4. Yellow asterisks show that neurons expressing TRPV4 did not express CGRP or SP. Control shows preabsorption of TRPV4 antibody. Scale bar = 10 μm. D, RT-PCR of mouse and rat DRG showing amplification of transcripts for TRPV4. There were no signals when reverse transcriptase (RT) was omitted (control).
Figure 6
Figure 6
PAR2-induced sensitization of TRPV4 Ca2+ signals and currents in DRG neurons (A–F) and HEK-FLPTREX-TRPV4a cells (G–I) Neurons were pretreated for 20 min and HEK-FLPTREX-TRPV4a cells for 2 min with PAR2-AP, PAR2-RP or vehicle (Veh) before challenge with 4αPDD. A–C, [Ca2+]i records in rat DRG neurons. A, records of [Ca2+]i in DRG neurons challenged with 4αPDD (10 μm). B, maximal [Ca2+]i responses to 4αPDD (10 μm) expressed as percentage response in neurons pretreated with PAR2-RP (100%). Pretreatment with PAR2-AP (10 μm) increased 4αPDD-stimulated Ca2+ response, indicative of TRPV4 sensitization (*P < 0.05, Student's t test). C, effects of inhibitors of second messenger kinases on PAR2-induced sensitization of Ca2+ signals to 4αPDD. Results are expressed as percentage of response to 4αPDD in neurons pretreated with PAR2-AP (100%). H-89 (10 μm) and GF109203X (GFX) 1 μm inhibited PAR2-induced sensitization of Ca2+ responses to 4αPDD (*P < 0.05, ANOVA and Dunnett's test). D–F, whole-cell currents of mouse DRG neurons. D, whole-cell currents recorded during voltage ramp (−100 mV to +100 mV every 15 s) before and during application of 4αPDD (10 μm). E, current densities at −80 mV and +80 mV. PAR2-AP (10 μm) increased 4αPDD-mediated current density (**P < 0.01; *P < 0.02, Student's t test). F, proportion of neurons that responded to 4αPDD (10 μm) by activation of an outwardly rectifying current. G–H, whole-cell currents of HEK-FLPTREX-TRPV4a. G, whole-cell currents recorded during voltage ramp (−100 mV to +100 mV every 15 s) before and during application of 4αPDD (0.5 μm). H, current densities at −80 mV and +80 mV. PAR2-AP (100 μm) increased 4αPDD-mediated current density (**P < 0.01; *P < 0.05, Student's t test). I, effects of antagonists of signalling pathways on PAR2-induced sensitization of currents to 4αPDD. H-89 (3 μm) and calphostin C (CaC) 2 μm inhibited sensitization (*P < 0.05; Student's t test). In A–I, numbers in parentheses refer to the number of cells.
Figure 7
Figure 7
Localization of immunoreactive TRPV4, CGRP or SP in dorsal horn of rat spinal cord Control shows preabsorption of TRPV4 antibody with antigen used for immunization. White arrows show colocalization of TRPV4 with CGRP and SP in some fibres of superficial laminae I and II. Scale bar = 10 μm.
Figure 8
Figure 8
TRPV4-mediated peptide release from rat dorsal horn Effects of 4αPDD (10–100 μm) (A) and hypotonic stimulus (228 mosmol l−1) (B) on release of CGRP (left panels) and SP (right panels) from superfused slices of dorsal spinal cord. −[Ca2+]o denotes Ca2+-free solution and Caps denotes pretreatment with capsaicin. 4αPDD and hypotonic stimulus induced release of CGRP and SP, and release required extracellular Ca2+ ions and was prevented by capsaicin pretreatment. *P < 0.05 compared to vehicle; ANOVA and Bonferroni's test. C and D, PAR2-induced sensitization of neuropeptide release from dorsal spinal cord. Effects of preincubation with PAR2-AP, PAR2-RP (both 10 μm) or vehicle for 20 min on release of immunoreactive CGRP (left panels) and SP (right panels) in response to 4αPDD (C) or hypotonic stimulus (D). Pretreatment with PAR2-AP increased release of CGRP and SP in response to 4αPDD and hypotonic stimulus, indicative of TRPV4 sensitization. *P < 0.05 compared to vehicle; ANOVA followed by Bonferroni's test. n = 6–9 experiments.
Figure 9
Figure 9
Role of TRPV4 in PAR2-induced mechanical hyperalgesia Frequency of paw withdrawal to stimulation with a von Frey hair under basal conditions, after intraplantar injection of 4αPDD or PAR2-AP alone, or after injection of PAR2-AP followed 5 min later by 4αPDD (A), and distilled water or PAR2-AP alone, or after injection of PAR2-AP followed 5 min later by distilled water (B). When given alone, 4αPDD (10 μl of 50 μm solution) and PAR2-AP (1 μg in 10 μl saline), but not hypotonic stimulus (10 μl of 17 mosmol l−1), increased the frequency of paw withdrawal in TRPV4+/+ but not TRPV4−/− mice, indicating that TRPV4 mediates 4αPDD- and PAR2-AP-induced mechanical hyperalgesia. Preinjection of PAR2-AP enhanced responses to 4αPDD and hypotonic stimulus in TRPV4+/+ but not TRPV4−/− mice, indicating that PAR2 sensitizes TRPV4 to cause mechanical hyperalgesia. ***P < 0.001; *P < 0.05 compared to vehicle; †††P < 0.001 compared to TRPV4+/+. ANOVA and Bonferroni's test. N = 6–9 animals.
Figure 10
Figure 10
Proposed model of protease-induced mechanical hyperalgesia Proteases that are generated during inflammation (1) activate PAR2 on afferent nerve endings in peripheral tissues (2). PAR2 couples to activation of second messenger kinases (3) that may phosphorylate and sensitize TRPV4 (4), resulting in enhanced influx of Na+ and Ca2+ ions (5) and elevated release of CGRP and SP in the dorsal horn in response to mechanical stimuli (6). CGRP and SP activate their receptors on spinal neurons (CGRP, calcitonin-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1); SP, neurokinin 1 receptor (NK1R)), resulting in enhanced transmission of nociceptive signals and mechanical hyperalgesia.
See this image and copyright information in PMC

Comment in

  • Pain TRP-ed up by PARs.
    Surprenant A. Surprenant A. J Physiol. 2007 Feb 1;578(Pt 3):631. doi: 10.1113/jphysiol.2006.126425. Epub 2006 Dec 21. J Physiol. 2007. PMID: 17185331 Free PMC article. No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alessandri-Haber N, Dina OA, Joseph EK, Reichling D, Levine JD. A transient receptor potential vanilloid 4-dependent mechanism of hyperalgesia is engaged by concerted action of inflammatory mediators. J Neurosci. 2006;26:3864–3874. - PMC - PubMed
    1. Alessandri-Haber N, Joseph E, Dina OA, Liedtke W, Levine JD. TRPV4 mediates pain-related behavior induced by mild hypertonic stimuli in the presence of inflammatory mediator. Pain. 2005;118:70–79. - PubMed
    1. Alessandri-Haber N, Yeh JJ, Boyd AE, Parada CA, Chen X, Reichling DB, Levine JD. Hypotonicity induces TRPV4-mediated nociception in rat. Neuron. 2003;39:497–511. - PubMed
    1. Amadesi S, Cottrell GS, Divino L, Chapman K, Grady EF, Bautista F, Karanjia R, Barajas-Lopez C, Vanner S, Vergnolle N, Bunnett NW. Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cε- and A-dependent mechanisms in rats and mice. J Physiol. 2006;575:555–571. - PMC - PubMed
    1. Amadesi S, Nie J, Vergnolle N, Cottrell GS, Grady EF, Trevisani M, Manni C, Geppetti P, McRoberts JA, Ennes H, Davis JB, Mayer EA, Bunnett NW. Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J Neurosci. 2004;24:4300–4312. - PMC - PubMed

Publication types

MeSH terms